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The clinical course and eventual outcome, or prog-
nosis, of complex diseases varies enormously
between affected individuals. This variability criti-
cally determines the impact a disease has on a
patient’s life but is very poorly understood. Here,
we exploit existing genome-wide association study
data to gain insight into the role of genetics in prog-
nosis. We identify a noncoding polymorphism in
FOXO3A (rs12212067: T > G) at which the minor (G)
allele, despite not being associated with disease
susceptibility, is associated with a milder course of
Crohn’s disease and rheumatoid arthritis and with
increased risk of severemalaria. Minor allele carriage
is shown to limit inflammatory responses in mono-
cytes via a FOXO3-driven pathway, which through
TGFb1 reduces production of proinflammatory cyto-
kines, including TNFa, and increases production of
anti-inflammatory cytokines, including IL-10. Thus,we uncover a shared genetic contribution to prog-
nosis in distinct diseases that operates via a
FOXO3-driven pathway modulating inflammatory
responses.
INTRODUCTION
Insights obtained from genetic experiments, including genome-
wide association studies (GWASs), have substantially advanced
our understanding of complex disease biology, and specifically
of the processes that drive disease development (Jostins et al.,
2012). It is important to remember, however, that disease devel-
opment is only one aspect of disease biology. Equally important
from a clinical standpoint is the biology that determines the
course a disease takes following its development (prognosis).
Variability in prognosis is observed in most complex diseases
and directly impacts upon patient well-being, often to a greater
extent than the diagnosis itself. Despite this, the determinants
of prognosis in most diseases remain poorly understood and
largely unaddressed by those genetic technologies that have
yielded such insights into disease development.Cell 155, 57–69, September 26, 2013 ª2013 The Authors 57
This knowledge imbalance is exemplified in Crohn’s disease
(CD), a chronic, relapsing-remitting form of inflammatory bowel
disease thought to be driven by aberrant immune responses to
intestinal bacteria. CD has been a major beneficiary of GWAS
technology, with over 140 risk loci having been identified (Jostins
et al., 2012), though only one of these has been shown to corre-
late with clinical outcome in CD (Helio¨ et al., 2003). Such obser-
vations have led to criticisms of the utility of GWAS results in
translational medicine (McClellan and King, 2010) and raise
questions as to whether genetics meaningfully contributes to
prognosis in complex disease.
We have recently shown that common transcriptional differ-
ences involving the IL-2 and IL-7 cytokine-signaling pathways
correlate with prognosis in several diseases, including CD
(McKinney et al., 2010; Lee et al., 2011). Here, we perform a
candidate gene study to address whether genetic variation in
these immune pathways, which have not been associated with
the development of CD, might associate with disease prognosis
and, if so, to understand the biological mechanisms responsible.
To answer this question, we determined that a ‘‘within-cases’’
association analysis would be required, in which the genetic pro-
files of patients with contrasting disease courses could be
directly compared. To achieve this, we used a subset of geno-
type data relating to the IL-2 and IL-7 pathways from an existing
GWAS data set (Wellcome Trust Case Control Consortium,
2007) and exploited allied phenotypic data to identify groups of
patients with either particularly aggressive or indolent CD. This
led to the identification of a noncoding single-nucleotide poly-
morphism (SNP) in FOXO3A that associates with prognosis in
CD, despite not being a disease-associated variant (Jostins
et al., 2012). FOXO3A encodes FOXO3, a member of the fork-
head box O family of transcription factors, which also includes
FOXO1 and FOXO4 (Accili and Arden, 2004). These proteins
are widely expressed and regulate diverse transcriptional pro-
grams including cell-cycle control, metabolism, regulatory
T cell development, and apoptosis (Burgering and Kops, 2002;
Modur et al., 2002; Nakae et al., 2008; Harada et al., 2010; Ker-
diles et al., 2010; Ouyang et al., 2010). Although many of these
roles are redundant between FOXO family members (Accili and
Arden, 2004), FOXO3 has been reported to have nonredundant
roles in suppressing inflammatory cytokine production by den-
dritic cells (Dejean et al., 2009; Watkins et al., 2011) and in
limiting the inflammatory sequelae of viral infections (Litvak
et al., 2012). Here, we show that during inflammatory responses,
in which FOXO3 is exported from the nucleus to the cytoplasm,
its reaccumulation in the nucleus is dependent on transcription
and de novo protein production, and demonstrate that allelic
variation at the prognosis-associated SNP regulates this reaccu-
mulation by controlling FOXO3A transcription. Earlier recovery of
nuclear FOXO3, which occurs if the indolent disease-associated
allele is present, initiates a TGFb1-dependent pathway in mono-
cytes that reduces production of proinflammatory cytokines,
including TNFa, and increases production of the anti-inflamma-
tory cytokine, IL-10—changes consistent with a more indolent
disease course. Furthermore, we show that genetic variation at
this SNP is also associated with prognosis in rheumatoid arthritis
and malaria—other diseases in which these cytokines are impli-
cated. These associations were consistent with the role for these58 Cell 155, 57–69, September 26, 2013 ª2013 The Authorscytokines in each disease, and suggest that this pathwaymay be
generally important in diseases in which these cytokines are
involved. Collectively, therefore, these data reveal a pathway
by which FOXO3 can abrogate inflammatory responses, and un-
cover a shared genetic contribution to the prognosis of distinct
diseases that impacts upon this pathway and is distinct from
the genetic contribution to disease development.
RESULTS
Prognosis-Based Association Study in Crohn’s Disease
Subgroups of patients with either particularly aggressive or
indolent CD were identified within an existing GWAS cohort
(Wellcome Trust Case Control Consortium, 2007) using pheno-
typic data. Aggressive CD (n = 668) was defined as that for which
two or more immunomodulator therapies and/or intestinal re-
sections had been required (treatments reserved for patients
with frequently flaring or complicated CD). Indolent CD (n =
389) was defined as disease of greater than 4 years duration,
for which immunomodulators or intestinal resections had never
been required. Eighty-one genes involved in IL-2 or IL-7 signaling
were identified from published literature and pathway libraries
(KEGG, Kanehisa and Goto, 2000; Biocarta, http://www.
biocarta.com) (Table S1 available online). These pathways
were selected because we have previously shown that differ-
ences within them correlate with prognosis in several diseases,
including CD, and yet unlike a number of other disease-asso-
ciated cytokines, they have not been implicated in disease
development (McKinney et al., 2010; Lee et al., 2011). The allele
frequency at 1,134 SNPs within these genes was then compared
between the indolent and aggressive CD subgroups (Figure S1).
The effect of population structure on the results was assessed by
three separate methods and shown to beminimal (genomic con-
trol inflation factor 1.04, see Extended Experimental Proce-
dures). Replication of the three most significant associations
was then sought in three independent cohorts, each similarly
divided into indolent and aggressive cases (Table S2). The prog-
nostic association of rs12212067, an intronic SNP within
FOXO3A, was replicated in all three cohorts, with the minor (G)
allele being consistently more common in patients with indolent
CD (combined p value = 2.1 3 108, Tables 1 and S3). Notably,
this SNP was not associated with risk for CD either in the GWAS
used for this study (p = 0.88)—a sample of 1,748 cases and 2,938
controls (Wellcome Trust Case Control Consortium, 2007)—or
in a larger meta-analysis (p = 0.99) of 6,333 cases and 15,056
controls (Franke et al., 2010), which suggests that if it does influ-
ence disease risk, its effect size is negligible.
rs12212067 Regulates Transcription of FOXO3A during
Inflammation
To investigate how genetic variation at this locus might influence
prognosis in CD, we first examined whether rs12212067 was
in linkage disequilibrium (LD) with a coding variant that could
affect protein structure or function. Using sequence data from
the 1000 Genomes Project Consortium et al. (2010) we identified
all of the SNPs in LD (r2 > 0.5) with rs12212067, but none of these
were exonic (Table S4 and Figure S2). Indeed, of the 45 coding
variants that have been described within FOXO3A (dbSNP,
Table 1. Association of rs12212067 with Prognosis in CD
Cohort na MAF (Aggressive) MAF (Indolent) Odds Ratio (95% CI) p Value
Primary cohort (WTCCC CD GWAS) 1,057 (668, 389) 0.084 0.131 0.61 (0.46–0.83) 6.16 3 104
Replication cohort 1 (UK - TaqMan) 701 (344, 357) 0.094 0.129 0.71 (0.49–1.00) 0.025
Replication cohort 2 (NZ - TaqMan) 226 (136, 90) 0.070 0.128 0.51 (0.26–1.02) 0.029
Replication cohort 3 (UK - Immunochip) 1,001 (670, 331) 0.083 0.133 0.59 (0.44–0.81) 6.50 3 104
Combined analysis 2,985 (1,818, 1,167) 0.084 0.131 0.62 (0.52–0.73) 2.09 3 108
Aggressive CD, patients requiringR two immunomodulators and/or intestinal resections; Indolent CD, patients with > 4 years follow-up, no immuno-
modulators or intestinal resections. p values calculated with Cochran-Armitage test (primary cohort) and Fisher’s exact test (replication cohorts and
combined analysis). Odds ratios refer to the minor (G) allele and aggressive Crohn’s disease (CD). WTCCC, Wellcome Trust Case Control Consortium;
UK, United Kingdom, NZ, New Zealand, MAF, minor allele frequency; CI, confidence interval. See also Figure S1 and Tables S1, S2, S3, S4.
aTotal sample size (Aggressive, Indolent).http://www.ncbi.nlm.nih.gov/projects/SNP) none were in any
demonstrable LD with rs12212067: T > G (r2 < 0.001, data not
shown). This implies that noncoding variation is likely to drive
the association. The majority of complex disease-associated
SNPs are also noncoding and are assumed to affect gene
expression, though in most cases this has not been confirmed
(McClellan and King, 2010). To ascertain whether rs12212067:
T > G, or a variant in strong LD with it, might influence gene
expression, we used a clone based allele-specific expression
assay to analyze FOXO3A transcription in monocytes from
heterozygous individuals (obtained from a genotype-selectable
bioresource; http://www.cambridgebioresource.org.uk). This
facilitates a direct comparison between the amount of FOXO3A
pre-mRNA that is transcribed from each allele or haplotype and
ensures that external factors affect both alleles equally. Under
basal (unstimulated) conditions, the ratio of major (T) to minor
(G) alleles in FOXO3A pre-mRNA was no different to that
observed in genomic DNA (in which it is inherently 1:1), indicating
that allele-specific expression did not occur. However, following
stimulation with lipopolysaccharide (LPS), a toll-like receptor 4
(TLR4) ligand, we observed consistent allele-specific differences
in transcription, with over twice as much FOXO3A being
transcribed from the DNA strand containing the minor G allele
(associated with indolent CD) than from the strand containing
the major T allele (Figure 1A).
Genetic Variation at rs12212067 Modulates
Inflammatory Cytokine Production by Monocytes
To determine whether this difference in FOXO3A transcription
had functional consequences, we stimulated peripheral blood
mononuclear cells (PBMC) from healthy individuals, who were
homozygous for either the minor or major allele at rs12212067,
and measured cytokine production. We initially focused upon
TNFa, the archetypal proinflammatory cytokine in CD (Khor
et al., 2011) and target of the most effective medical therapy
(Krygier et al., 2009); and IL-10, an anti-inflammatory cytokine,
which when deleted produces one of the best mouse models
of IBD (Rennick et al., 1997); and genetic variants of which are
associated with CD (Jostins et al., 2012). Following LPS stimula-
tion, we observed striking genotype-specific differences in the
production of these cytokines, with PBMC from minor (G) allele
homozygotes secreting less TNFa than those from major (T)
allele homozygotes. PBMC from minor allele homozygotes alsosecreted relatively more IL-10 in response to higher concentra-
tions of LPS (Figure 1B). This pattern of cytokine production
implies that, under these conditions, minor allele homozygotes
generate lesser inflammatory responses. There were no geno-
type-specific differences in the proportion, activation status or
immunophenotype of leukocyte subsets within PBMC that could
explain this result (Table S5). These included regulatory T cells
and dendritic cells, in which FOXO3 has specific roles (Dejean
et al., 2009; Kerdiles et al., 2010).
To ascertain which cell population was responsible for the dif-
ferences in cytokine production, we used flow cytometry to iden-
tify the TNFa and IL-10 producing cells. Following stimulation
with LPS (100 ng/ml), production of both cytokines could be
detected within CD14+ monocytes, but not within CD3+ T cells
or CD19+ B cells (Figure 1C). Of note, differences were again
observed between the genotypes, with less TNFa and more IL-
10 being produced by monocytes from minor allele homozy-
gotes (Figure S3). To determine whether this phenomenon was
cell-intrinsic or due to another cell type influencing monocyte
cytokine production, we purified monocytes and stimulated
them in isolation. Despite removing the influence of other cell
types, we observed the same genotype-specific differences in
cytokine production (Figure 1D), implying that the effect was
monocyte intrinsic. We then examined whether the differences
were specific to stimulation via TLR4 or would also occur with
other TLR ligands (Pam3Cys4 [TLR1/2], Poly(I:C) [TLR3],
Flagellin [TLR5], and CpG [TLR9]). We observed the same recip-
rocal differences in TNFa and IL-10 production in response to all
of these ligands except Poly(I:C), which induced little TNFa and
IL-10 production consistent with previous reports (Lundberg
et al., 2007) (Figure 1E). Thus, the genotype-specific differences
in cytokine production arise frommonocytes but can be induced
by several pathogen-associated molecular patterns.
We then examined the production of other proinflammatory
cytokines to determine whether these also differed by genotype.
We quantified GM-CSF, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, and IL-
12p40 and observed that, as well as producing less TNFa,
monocytes from minor (G) allele homozygotes also produced
less IL-1b, IL-6, and IL-8 compared to those from major (T) allele
homozygotes (Figures 1F and S4). Notably, these cytokines
constitute a major part of the innate immune response to patho-
gens (Auffray et al., 2009) and can influence the phenotype of
T cells (Dejean et al., 2009).Cell 155, 57–69, September 26, 2013 ª2013 The Authors 59
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Figure 1. Genotype at rs12212067 Drives Allele-Specific Expression of FOXO3A and Modulates Inflammatory Cytokine Production in
Monocytes
(A) Allele-specific expression assay showing the ratio of rs12212067 alleles in genomic DNA (gDNA) and complementary DNA (cDNA; synthesized from pre-
mRNA) from peripheral monocytes of heterozygous individuals. Ninety-six colonies were genotyped per individual per condition (either unstimulated [unstim.] or
stimulated with 100 ng/ml LPS [stim.]); n = 6.
(B) TNFa and IL-10 production by PBMC from minor (G) and major (T) allele homozygotes at rs1221267 following 24 hr stimulation with LPS; n = 15 per group,
assayed in triplicate.
(C) Intracellular staining of TNFa and IL-10 production in LPS-stimulated (100 ng/ml) CD3+ T cells, CD19+ B cells and CD14+monocytes. Isotype control shown as
shaded histogram. Results representative of 20 experiments.
(D) TNFa and IL-10 production by purifiedmonocytes fromminor andmajor allele homozygotes following 24 hr stimulation with LPS (100 ng/ml); n = 11 per group,
assayed in triplicate. 20 of these individuals had provided samples used in B.
(E) TNFa and IL-10 production by PBMC from minor and major allele homozygotes following 24 hr stimulation with other TLR ligands; n = 11 per group (same
individuals’ samples as D), assayed in triplicate.
(F) IL-1b, IL-6, and IL-8 production by purified monocytes from minor and major allele homozygotes following 24 hr stimulation with LPS (same samples as in D),
n = 11 per group. Data are represented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figures S2, S3, S4 and Tables S4 and S5.
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Figure 2. Genotype at rs12212067 Influences the Nuclear Recovery
of FOXO3 during Cellular Activation
(A) The subcellular localization of FOXO3 in monocytes during LPS stimulation
(representative images). FOXO3 (red) and nucleus (DAPI, blue).
(B) The ratio of nuclear to cytoplasmic FOXO3 over time (mean immunofluo-
rescence intensity) in LPS-stimulated monocytes from minor (G) and major
(T) allele homozygotes at rs12212067 (100 ng/ml, n = 10). The dotted line
indicates transition from higher signal in nucleus (above) to cytoplasm (below).
(C–D) Production of TNFa (C) and IL-10 (D) by monocytes analyzed in (B).
Cytokines were quantified in triplicate by ELISA. Data are represented as
mean ± SEM, *p < 0.05, **p < 0.01.
See also Figure S5.Differences in FOXO3A Transcription during
Inflammation Determine when FOXO3 Reaccumulates
within the Nucleus
We next considered how differences in FOXO3A transcription
might affect cytokine production. Because the downstream tran-
scriptional programof FOXO3 is largely controlled byposttransla-
tionalmodifications that determinewhether it is retainedwithin, or
excluded from, the nucleus (Hedrick, 2009), we first examined
how the intracellular localization of FOXO3 changed as mono-
cytes were stimulated (Figure 2A). TNFa and IL-10 production
werealsomeasured.Weshowed that inunstimulatedmonocytes,
most FOXO3 was nuclear, and TNFa production was low. Upon
LPS stimulation, FOXO3was translocated out of the nucleus (Fig-
ure 2A) and a linear increase in TNFa production was observed.
This process occurred similarly inminor andmajor allele homozy-
gotes, until very little nuclear FOXO3 remained after 4 hr (Fig-
ure 2B). Thereafter, a gradual increase in the amount of nuclear
FOXO3 was observed (termed ‘‘nuclear recovery’’), which corre-
lated with reduced TNFa and increased IL-10 production. Strik-
ingly, this nuclear recovery phase occurred considerably faster
in minor (G) allele homozygotes than in major (T) allele homozy-
gotes and correlatedwith an earlier reduction in TNFa production
and an earlier increase in IL-10 production (Figures 2B–2D). This
difference is consistent with the allele-specific expression differ-
ences and implies that, during inflammation, increased FOXO3A
transcription in carriersof theminor (G) allele leads to faster recov-
ery of nuclear FOXO3. This also suggests that de novo protein
synthesis, rather than nuclear translocation of cytoplasmic
FOXO3, is responsible for nuclear recovery; consistent with the
observation that once FOXO3 is translocated into the cytoplasm,
it is targeted for proteasomal degradation (Yang et al., 2008). This
was confirmed by showing that if protein synthesis was inhibited,
nuclear recoveryof FOXO3wassubstantially retarded (FigureS5).
The Effect of rs12212067 on Monocyte Cytokine
Production Is TGFb1 Dependent
Next we investigated how the earlier recovery of nuclear FOXO3
might alter inflammatory cytokine production. In mice, silencing
Foxo3a has been shown to abrogate production of TGFb1 (Wat-
kins et al., 2011), an anti-inflammatory cytokine that can modu-
late production of other cytokines (Musso et al., 1990; Fadok
et al., 1998). To determine whether TGFb1 might contribute to
the observed differences in cytokine production, we re-exam-
ined the supernatants from the earlier experiments. We found
that relatively more TGFb1 had been secreted by PBMC and
monocytes from minor (G) allele homozygotes (Figure 3A) with
the greatest difference, and highest concentrations, being pre-
sent in the monocyte supernatants—implicating these cells as
the major source of TGFb1. To determine whether this difference
might contribute to the differences in TNFa and IL-10 production,
we examined the effects of blocking TGFb1 signaling. Strikingly,
we observed that the genotype-specific differences in TNFa and
IL-10 production were abolished if TGFb1 signaling was inhibited
(Figure 3B)—suggesting that a TGFb1-dependent mechanism
was responsible. In support of this, differences in TGFb1 titers
from minor and major allele homozygotes were also detected
in the samples from the earlier time-course experiment, with
the kinetics of TGFb1 production correlating with the differencesCell 155, 57–69, September 26, 2013 ª2013 The Authors 61
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Figure 3. A TGFb1-Dependent Mechanism Is Responsible for the Effect of rs12212067 on Monocyte Cytokine Production
(A) TGFb1 production by PBMC (n = 20 per group) andmonocytes (n = 13 per group) fromminor (G) andmajor (T) allele homozygotes at rs1221267 following 24 hr
stimulation with LPS (100 ng/ml), assayed in triplicate.
(B) TNFa and IL-10 production by PBMC from minor and major allele homozygotes following 24 hr stimulation with LPS (100 ng/ml) in the presence of a TGFb1-
neutralizing antibody or isotype control; n = 10 per group, assayed in triplicate.
(C) Production of TGFb1 by monocytes in the time-course experiment shown in Figure 2, measured in triplicate by ELISA.
(D) The effect of TGFb1 or a TGFb1-neutralizing antibody upon TNFa and IL-10 production by LPS-stimulated monocytes, assessed using flow cytometry (mean
fluorescence intensity, MFI). Data are log2 transformed following normalization, Wilcoxon signed-rank test; n = 6. Data are represented asmean ± SEM, *p < 0.05,
**p < 0.01, NS, nonsignificant.in nuclear recovery of FOXO3 (Figure 3C). Moreover, the addition
of exogenous TGFb1 to stimulated monocytes of either geno-
type led to less TNFa and more IL-10 production—consistent
with the differences observed between the genotypes—whereas
blockade of TGFb1 had the opposite effect (Figure 3D). This sug-
gests that endogenous TGFb1 production plays an important
regulatory role in monocyte-driven inflammatory responses.
FOXO3 Regulates TGFb1 Production in Stimulated
Monocytes
Although these data implicate a TGFb1-dependent mechanism
in driving the genotype-specific differences in cytokine produc-
tion, it was unclear how the earlier recovery of nuclear FOXO3
might mediate this. To determine whether FOXO3 directly regu-
lated TGFb1 production, we analyzed the TGFb1 promoter and62 Cell 155, 57–69, September 26, 2013 ª2013 The Authorsidentified several sites at which FOXO3 was predicted to bind
(Figure 4A and Table S6). To establish whether this interaction
occurred during monocyte activation, we immunoprecipitated
FOXO3 from stimulated monocytes and found that the DNA to
which it was bound included the predicted binding site from
the TGFb1 promoter (Figure 4B), confirming that a direct pro-
tein-DNA interaction occurs. To determine the result of this inter-
action, we silenced FOXO3A in two monocyte cell lines, U937
(Sundstro¨m and Nilsson, 1976) and MONO-MAC6 (Ziegler-
Heitbrock et al., 1988), and examined the effect on TGFb1 tran-
scription. In both, we showed that when FOXO3A was silenced,
transcription from the TGFb1 promoter was reduced, confirming
that the FOXO3-TGFb1 interaction promotes TGFb1 transcrip-
tion (Figure 4C). Together, these data reveal that FOXO3 induces
TGFb1 expression via a direct protein-DNA interaction in
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Figure 4. FOXO3 Regulates TGFb1 Production in Stimulated Monocytes
(A) Jaspar sequence logo of the FOXO3-binding site (http://jaspar.genereg.net).
(B) ChIP-qPCR analysis of the TGFb1 promoter following FOXO3 immunoprecipitation. Enrichment for each region is shown relative to input (5 ng) and normalized
against the results of a negative control immunoprecipitate (polyclonal IgG). Validated positive and negative control genomic regions were used. Controls shown
are HBB (negative) and a region upstream of MSTN (positive). n = 3.
(C) Luciferase reporter assay showing effect of silencing FOXO3A on transcription from the TGFb1 promoter in twomonocyte cell lines (U937 andMONO-MAC6).
No transfection (Nil) and scrambled controls (Scr) are shown. Data representive of three experiments, each with seven biological replicates.
(D) Apoptosis in monocytes from minor (G) and major (T) allele homozygotes at rs12212067 following 24 hr stimulation with LPS (100 ng/ml); assessed by flow
cytometry (7-AAD+, Annexin V+), n = 12 per group.
(E) The change in the concentration of mono- and oligonucleosomes in the cytoplasm (apoptosis) and supernatant (necrosis) of monocytes following LPS
stimulation (24 hr, 100 ng/ml), assessed in triplicate by ELISA. Dotted lines link paired samples; Wilcoxon signed-rank test, n = 8 per group. Data are represented
as mean ± SEM, *p < 0.05, **p < 0.01, NS, nonsignificant.
See also Figure S6 and Table S6.stimulated monocytes and explain how the earlier recovery of
nuclear FOXO3 could modulate TNFa and IL-10 production in
a TGFb1-dependent manner.
TGFb1 has also been implicated in the modulation of immune
responses by apoptotic cells (Fadok et al., 1998), whereasFOXO3 is known to be proapoptotic (Brunet et al., 1999). This
raised the possibility that earlier nuclear recovery of FOXO3
might also augment TGFb1 production indirectly via apoptosis
induction. To examine this, we quantified apoptosis in PBMC
following LPS stimulation (using Annexin V and 7-AAD) andCell 155, 57–69, September 26, 2013 ª2013 The Authors 63
observed that more occurred in minor (G) allele homozygotes
(Figure 4D), consistent with the earlier recovery of nuclear
FOXO3 in this genotype. To exclude a contribution from necrotic
cells to this result, we quantifiedmono- and oligonucleosomes in
the supernatant (necrosis) and cytoplasm (apoptosis) of PBMC
from another cohort of minor and major allele homozygotes
and again observed more apoptosis in minor allele homozygotes
following stimulation (Figure 4E). We also confirmed that stimu-
lated monocytes produced less TNFa and more IL-10 in the
presence of autologous apoptotic cells and that this could be
abrogated by TGFb1-blockade (Figure S6). These data imply
that FOXO3 might drive TGFb1 production not only via a direct
interaction with its promoter, but also indirectly via the control
of apoptosis.
FOXO3 has also been shown to mediate some of the down-
stream components of TGFb1 signaling (Wildey and Howe,
2009), raising the possibility that earlier nuclear recovery might
amplify some of the effects of TGFb1 production. However, we
did not detect any genotype-specific differences in the transcrip-
tion of 11 genes whose activation by TGFb1 is FOXO dependent
(Gomis et al., 2006) (data not shown), consistent with reports that
this role is redundant between FOXO family members (Seoane
et al., 2004).
Foxo3Deficiency Leads to IncreasedDiseaseSeverity in
a Mouse Model of Colitis
Collectively, these data provide a plausible mechanism to
explain the association of the haplotype tagged by rs12212067
with prognosis in CD, particularly given the role that circulating
monocytes and their intestinal derivatives play in CD pathogen-
esis (Geissmann et al., 2010; Khor et al., 2011; Bain et al., 2013).
To provide further evidence of how altered FOXO3 function
might influence intestinal inflammation, we used an in vivomodel
of inflammatory bowel disease. Using dextran sodium sulfate
(DSS), we induced colitis in mice harboring a missense mutation
in the highly conserved Forkhead DNA-binding domain of Foxo3,
known to abrogate its function (Foxo3aMommeR1/MommeR1mice—
from here termed Foxo3a/, Youngson et al., 2011) and
compared the severity of the resulting disease with that
observed in heterozygous (Foxo3a+/) and wild-type mice
(Foxo3a+/+). We showed that, consistent with the in vitro data,
reduced Foxo3a transcriptional activity predisposed to a more
severe colitis. This was evident histologically (Figures 5A and
5B) and by greater losses in body weight (Figure 5C), increased
colonic weight, and reduced colonic length (Figures 5D and 5E).
Moreover, the colitis in Foxo3a/ mice was characterized by
increased expression of proinflammatory cytokines and reduced
expression of IL-10 in the diseased colons, which mirrored our
in vitro data (Figures 5F and S7). Importantly, these differences
could not be solely attributed to an increase in activated myeloid
cells within the colon, as they were still present after normaliza-
tion against CD11b, a myeloid activation marker (Figure 5F).
Genetic Variation in FOXO3A Is Associated with
Prognosis in Rheumatoid Arthritis and Malaria
The pathway we have identified—by which genetic variation in
FOXO3A can modulate inflammatory cytokine production in
monocytes—would not only be expected to influence the64 Cell 155, 57–69, September 26, 2013 ª2013 The Authorsoutcome of CD, but also of other diseases involving these cyto-
kines. Rheumatoid arthritis (RA) is a chronic inflammatory poly-
arthritis, in which autoimmune-mediated synovial inflammation
can lead to progressive joint destruction and disability. The
pathogenesis of RA involves many cytokines, including TNFa,
IL-6, and IL-10, with blockade of the first two being effective ther-
apies (Feldmann and Maini, 2008). We therefore genotyped
rs12212067 in two prospectively collected cohorts of RA
patients, who had had serial radiographs of their hands and
feet at regular intervals (Symmons and Silman, 2003; James
et al., 2004), and examined whether the rs12212067: T > G
haplotype was associated with clinical outcome. Of note, this
SNP has not been associated with susceptibility to RA (Well-
come Trust Case Control Consortium, 2007). We confirmed
that the minor (G) allele, which associated with milder CD, was
also associated with a milder course of RA, characterized by
less joint damage over time (equivalent to a reduction of 1.5
Larsen units per copy of the G allele) (Tables 2 and S7). This is
consistent with the functional effects of allelic variation at this
SNP and suggests that prognosis in RA is also influenced by
FOXO3-dependent control of inflammatory responses.
Aside from their involvement in inflammatory disease, cyto-
kines such as TNFa, IL-6, and IL-10 also participate in immune
responses to infection. During initial infection with malaria—the
leading cause of childhood death in Africa—proinflammatory
cytokines, including TNFa, are released by monocytes and
macrophages to help kill parasites (Malaguarnera and Musu-
meci, 2002), whereas IL-10 inhibits this protective response
(Hugosson et al., 2004). We hypothesized that the effects of
rs12212067: T > Gwould impair parasite clearance and increase
the risk of severemalaria. To test this, we genotyped rs12212067
in separate cohorts of Kenyan (Williams et al., 2005) and Viet-
namese patients (Tran et al., 1996) who were admitted to hospi-
tal with severe P. falciparum malaria and ethnically matched
controls. In both cohorts, we found an association between the
minor (G) allele and increased susceptibility to severe malaria
(Tables 2 and S3), consistent with the predicted result of produc-
ing less TNFa and more IL-10 during initial infection.
DISCUSSION
Despite advances in complex disease genetics, remarkably little
attention has been paid to whether genetics contributes to as-
pects of disease biology beyond simple susceptibility. Here,
we identify a genetic variant in FOXO3A that associates with
the prognosis, but not diagnosis, of three distinct diseases;
CD, RA, and malaria. This observation has important implica-
tions for how we think about the genetics of complex disease
and introduces the concept that common variants can determine
the outcome of one or more diseases, without being associated
with the disease itself. By focusing more attention on this aspect
of disease biology, it may be possible to uncover new therapeu-
tic targets that are relevant in several diseases and also facilitate
the development of personalized medicine, both through more
accurate prediction of outcome and better targeted therapies.
FOXO3 has been linked to the regulation of immune responses
using systems biology (Litvak et al., 2012) and knockout mouse
models (Dejean et al., 2009), although whether this was relevant
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Figure 5. Loss of Foxo3a Activity Predisposes to More Severe Colitis in a Mouse Model
(A–F) Colitis was induced in littermate Foxo3a/, Foxo3a+/, and Foxo3+/+mice using 2%DSS (7 d). Results representative of two experiments each with 5 mice
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(B) Histological assessment of colitis severity, scored with a standard tool (Dieleman et al., 1998).
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(E) Colon length (day 12).
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See also Figure S7.in human disease, or even occurred physiologically in humans,
was unclear. By exploring the effects of the prognosis-associ-
ated variant, we have identified a pathway by which FOXO3
limits inflammatory responses in human monocytes through a
paracrine TGFb1-dependent mechanism and have confirmedthe importance of this pathway in an in vivo model. This, there-
fore, not only provides a molecular explanation for the associa-
tion of rs12212067: T > G with prognosis in each disease, but
also sheds light on the role of FOXO3 in regulating monocyte-
driven inflammation.Cell 155, 57–69, September 26, 2013 ª2013 The Authors 65
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66 Cell 155, 57–69, September 26, 2013 ª2013 The AuthorsIt is noteworthy that the prognostic association of this poly-
morphism appears to be mediated via monocytes, which are
known to be important in these inflammatory and infectious dis-
eases (Malaguarnera and Musumeci, 2002; Khor et al., 2011;
Bain et al., 2013; Davignon et al., 2013). CD pathogenesis, for
example, is thought to stem from a dysfunctional innate immune
response to intestinal bacteria by proinflammatory macro-
phages and dendritic cells (Khor et al., 2011)—both of which
derive from circulating monocytes (Geissmann et al., 2010; Riv-
ollier et al., 2012; Bain et al., 2013). The resulting production of
proinflammatory cytokines by these cells not only drives disease
activity but is also the target of the most effective therapy (Kry-
gier et al., 2009). Similarly, in RA, disease severity correlates
with the extent of synovial infiltration by monocytes/macro-
phages, and these can be targeted therapeutically (Mulherin
et al., 1996; Davignon et al., 2013).
Although our evidence points to an effect in monocytes, T cells
are also important in these diseases (Feldmann and Maini, 2008;
Khor et al., 2011). However, we did not detect any differences in
T cell phenotype in our experiments. This does not exclude a
T cell effect in vivo, but even if onewas seen, it may be secondary
to FOXO3-driven differences in cytokine production. This is
exemplified in infected Foxo3 deficient mice (a strain derived
independently of the Foxo3MommeR1 mice) where the resulting
T cell phenotype is due to enhanced inflammatory cytokine pro-
duction by myeloid cells (Dejean et al., 2009).
The importance of the FOXO3-driven pathway that we
describe, and its genetic regulation, may not only be limited
to disease. Several key elements of this pathway have been
independently associated with human longevity, including poly-
morphisms in FOXO3A (Kenyon, 2010) and lesser inflammatory
responses—characterized by less TNFa andmore IL-10 produc-
tion (Licastro et al., 2005). Whether the control of inflammatory
cytokine production by FOXO3 links these observations and
thereby influences lifespan is unknown but warrants further
investigation.
To date, over 1,000 GWASs have been performed to study the
role of genetics in disease susceptibility (Hindorff et al., 2013),
but very few have been re-examined since their initial publica-
tion. Our data demonstrate that further insights into disease
biology can be obtained using such data sets, and highlight
the potential to discover pathways that may be critically impor-
tant in disease biology but which were not revealed by the
same index studies.
In summary, therefore, we show that the role of genetics in
complex disease extends beyond a contribution to disease
development and describe a FOXO3-dependent pathway that
limits inflammatory responses and which, through its genetic
regulation, is independently associated with the prognosis of
distinct inflammatory and infectious diseases.
EXPERIMENTAL PROCEDURES
GWAS Reanalysis
Single-marker allelic association analysis was performed using post-QC geno-
typecalls (WellcomeTrustCaseControlConsortium,2007) for 1,134SNPswithin
81 genes implicated in IL-2 or IL-7 signaling (including 2 kb on either side to
encompass regulatory regions). Data were analyzed in PLINK (http://pngu.
mgh.harvard.edu/purcell/plink) using Cochran-Armitage tests to determine
statistical significance. Genotype frequencies were in Hardy Weinberg equilib-
rium (p > 0.05). The contribution of population structure to the association results
was assessed using structure (Pritchard et al., 2000a), the Genomic Control
method and a Breslow-Day test. Replication was sought in three independent
replication cohorts. See also Extended Experimental Procedures.
Genotyping
Non-GWAS genotyping was performed using TaqMan predesigned SNP gen-
otyping assays (Applied Biosciences), a custom genotyping chip (Illumina
Immunochip), or Sequenom MassArray technology, as indicated.
Cambridge BioResource
In vitro experiments were performed using blood samples from healthy volun-
teers, selected by genotype from a human bioresource (Cambridge
BioResource, http://www.cambridgebioresource.org.uk). All provided
informed consent. Samples were paired and age and sex matched. Investiga-
tors were blinded to sample genotype until study completion. Ethical approval
was obtained from Cambridgeshire Regional Ethics Committee.
Allele-Specific Expression
A clone-based allele-specific expression assay (Rainbow et al., 2008) was per-
formed using monocytes from six individuals heterozygous at rs12212067.
Genomic DNA and pre-mRNA were extracted and amplified, and allelic ratios
assessed by colony genotyping (TaqMan, 96 colonies per individual per
condition).
Cell Stimulations
Aliquots of 1 3 106 cells/ml were stimulated in Complete RPMI at 37C, 5%
CO2. 50 ml of each stimulus (or control) was used to produce the final concen-
trations. Cytokines were quantified in triplicate using cytometric bead arrays
(BD), ELISAs (Quantikine, R&D Systems) or MesoScale Discovery immunoas-
says (see Extended Experimental Procedures).
Immunofluorescence
Stimulated monocytes were fixed (4% PFA), blocked (2% gelatin), and stained
with anti-FOXO3 (Cell Signaling) conjugated to an AF594 secondary antibody.
Nuclear staining was performed using Hoechst dye. Images were captured on
a Zeiss LSM510 META Confocal Microscope and analyzed with Volocity soft-
ware (Perkin Elmer).
ChIP-qPCR
Chromatin from stimulated monocytes was sheared by water-bath sonication
(Bioruptor, Diagenode) and FOXO3 was immunoprecipitated with a ChIP-
grade anti-FOXO3 antibody (Abcam). Polyclonal IgG was used as a negative
control. Quantitative (q)PCR was performed for a region of the TGFb1 pro-
moter predicted to contain a FOXO3-binding site, along with six positive and
five negative controls (all previously validated in Eijkelenboom et al., 2013).
Input DNA was standardized (5 ng) and the data normalized to the results ob-
tained using a polyclonal IgG immunoprecipitation.
Luciferase Reporter Assays
A firefly hLuc vector containing the TGFb1 promoter (Promega), a pCMV renilla
control and two anti-FOXO3 siRNAs, or a scrambled control (Origene) were
transfected into U937 (Sundstro¨m and Nilsson, 1976) and MONO-MAC6 cells
(Ziegler-Heitbrock et al., 1988). Results were analyzed at 48 hr using the Dual-
Glo kit (Promega) and a Glomax reader (Promega).
Mice and DSS Colitis
C57BL/6 Foxo3aMommeR1/MommeR1 (Foxo3a/) mice were obtained from
Emma Whitelaw (QIMR) and bred at the Australian National University (ANU).
Colitis was induced in 8-week-old Foxo3a/, Foxo3a+/, and Foxo3a+/+
mice (littermates) using DSS (2% in drinking water, 7 days). Body weight
was assessed daily, and colon length and weight on day 12. Blinded histolog-
ical assessment was made using a standard scoring system (Dieleman et al.,
1998), and cytokine expression quantified by qPCR from sections of paraffin-
embedded colons. Approval was obtained from the ANU Animal Ethics Exper-
imentation Committee.Statistical Significance
Comparison of continuous variables between two groups was performed
using Mann-Whitney or Wilcoxon signed-rank tests where indicated. Two-
tailed tests were used as standard unless a specific hypothesis was tested.
The alpha value was 0.05, unless corrected for multiple-testing.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
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